Stock Events

Stock Events

Poniard Pharmaceuticals 

$0
2
-$0-90% Wednesday 13:30

Statistics

Day High
0
Day Low
0
52W High
0
52W Low
0
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

31OctExpected
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Q3 2022
0
0.33
0.67
1
Expected EPS
0
Actual EPS
0

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PARD. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
AMGEN
AMGN
Mkt Cap178B
Amgen is a biotechnology firm focused on human therapeutics, directly competing in the oncology segment with Poniard Pharmaceuticals.
Bristol-Myers Squibb
BMY
Mkt Cap118.87B
Bristol-Myers Squibb is a global biopharmaceutical company with a strong portfolio in cancer drugs, overlapping with Poniard's focus on oncology treatments.
Pfizer
PFE
Mkt Cap149.77B
Pfizer is involved in the development and commercialization of various pharmaceuticals, including cancer treatments, which competes with Poniard's oncology products.
Merck
MRK
Mkt Cap277.02B
Merck is a leading pharmaceutical company with a significant presence in the oncology market, directly competing with Poniard Pharmaceuticals in cancer treatment solutions.
Lilly(Eli) &
LLY
Mkt Cap862.01B
Eli Lilly and Company develops and sells pharmaceutical products, including cancer therapies, competing in the same space as Poniard Pharmaceuticals.
Gilead Sciences
GILD
Mkt Cap163.4B
Gilead Sciences is a biopharmaceutical company that develops and markets therapies in areas including oncology, competing with Poniard's cancer focus.
Novartis
NVS
Mkt Cap279.67B
Novartis is a global healthcare company that manufactures drugs, including those for cancer, which places them in direct competition with Poniard Pharmaceuticals.
Astrazeneca
AZN
Mkt Cap286.4B
AstraZeneca operates in various therapeutic areas, including oncology, making them a competitor to Poniard Pharmaceuticals in the cancer drug market.
Roche
RHHBY
Mkt Cap328.49B
Roche Holding AG focuses extensively on oncology drug development and marketing, competing with Poniard Pharmaceuticals in the cancer treatment arena.
Johnson & Johnson
JNJ
Mkt Cap546.9B
Johnson & Johnson engages in the creation of pharmaceuticals, including oncology drugs, competing with Poniard Pharmaceuticals in the healthcare sector.

About

Poniard Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of cancer therapeutics. Its lead platform product candidate includes Picoplatin, a platinum-based cancer therapy to treat multiple cancer indications, including small cell lung, colorectal, prostate, and ovarian cancers. The company has conducted a pivotal Phase III SPEAR trial of Picoplatin in the second-line treatment of patients with small cell lung cancer; Phase II trials evaluating picoplatin as a first-line treatment of metastatic colorectal cancer and castration-resistant prostate cancer; and a Phase I study evaluating an oral formulation of picoplatin in solid tumors. The company was formerly known as NeoRx Corporation and changed its name to Poniard Pharmaceuticals, Inc. in September 2006. Poniard Pharmaceuticals, Inc. was founded in 1984 and is based in Seattle, Washington.
Show more...
CEO
Dr. Robert F. Caspari
Employees
7
Country
United States
ISIN
US7324494001

Listings

STU
DE
NX1B.STU
OTC Link
US
PARD

0 Comments

Share your thoughts

FAQ

What is Poniard Pharmaceuticals stock price today?▼
The current price of PARD is $0 USD — it has decreased by -90% in the past 24 hours. Watch Poniard Pharmaceuticals stock price performance more closely on the chart.
What is Poniard Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Poniard Pharmaceuticals stocks are traded under the ticker PARD.
What were Poniard Pharmaceuticals earnings last quarter?▼
PARD earnings for the last quarter are 0 USD per share, whereas the estimation was 0 USD resulting in a +NaN% surprise. The estimated earnings for the next quarter are N/A USD per share.
How many employees does Poniard Pharmaceuticals have?▼
As of May 06, 2026, the company has 7 employees.
In which sector is Poniard Pharmaceuticals located?▼
Poniard Pharmaceuticals operates in the Health & Wellness sector.
When did Poniard Pharmaceuticals complete a stock split?▼
The last stock split for Poniard Pharmaceuticals was on November 23, 2011 with a ratio of 1:40.
Where is Poniard Pharmaceuticals headquartered?▼
Poniard Pharmaceuticals is headquartered in Seattle, United States.